Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial
| Autor: | Joseph Jankovic, Eduardo Tolosa, Elijahu Berkovich, Eli Eyal |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Parkinson's disease Post hoc Population Motor Activity Placebo Motor function Placebo group Cohort Studies chemistry.chemical_compound Double-Blind Method Internal medicine Medicine Humans education Baseline values Rasagiline education.field_of_study business.industry Parkinson Disease medicine.disease Neuroprotective Agents Neurology chemistry Indans Female Neurology (clinical) Geriatrics and Gerontology business |
| Zdroj: | Parkinsonismrelated disorders. 20(6) |
| ISSN: | 1873-5126 |
| Popis: | Background The ADAGIO study included a large cohort of patients with early PD (baseline total-UPDRS = 20) who were initially randomized to rasagiline and placebo, thereby allowing analyses of symptomatic efficacy. Methods Post-hoc analyses comparing the efficacy of rasagiline 1 mg/day (n = 288) versus placebo (n = 588) on key symptoms at 36 weeks, and on total-UPDRS scores over 72 weeks (completer population: rasagiline 1 mg/day n = 221, placebo n = 392) were performed. Results Treatment with rasagiline resulted in significantly better tremor, bradykinesia, rigidity and postural-instability-gait-difficulty scores at week 36 versus placebo. Whereas the placebo group experienced progressive deterioration from baseline (2.6 UPDRS points at week 36), patients in the rasagiline group were maintained at baseline values at week 60 (UPDRS-change of 0.3 points). At week 72, patients who had received continuous monotherapy with rasagiline experienced a worsening of only 1.6 points. Conclusions Treatment with rasagiline maintained motor function to baseline values for at least a year with significant benefits observed in all key PD motor symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect